What causes chemobrain? New insights
Chemobrain is a term used to describe the changes in cognitive abilities that some patients with cancer may experience, such as:
Fogginess of thinking Trouble recalling recent events Feeling slower in their thought processes Mental tasks requiring more effortIt commonly affects patients undergoing chemotherapy and sometimes other types of cancer treatments, and it may impact their quality of life.
What we know — and don’...
11 new research advances from the past year
Over the past year, MD Anderson researchers and clinicians have investigated the gut microbiome, examined the earliest genesis of lung adenocarcinoma...
Advances in small cell lung cancer classification
Most patients with lung cancer have non-small cell lung cancer. However, around 15% of patients have a less-common type called small cell...
What is theranostics?
You may have heard the term theranostics when reading about cancer treatments, but what does it mean? The word theranostics is a combination of the words “therapy” and “diagnostics,” and theranostics does just that. It uses radioisotopes to first image a patient’s tumor for diagnostics and then therapeutically treat that tumor.
We spoke with Charles Manning, Ph.D., a cancer systems imaging researcher, to learn more about how theranostics...
Innovative directions in immunotherapy research
Immunotherapy is a cancer treatment that uses a patient’s immune system to target their cancer cells. Some common types of immunotherapies...
How are targeted therapies used in lung cancer treatment?
Lung cancer is the third-most common type of cancer and the most common cause of cancer-related deaths in the United States, according to...
What’s new in leukemia research?
Leukemia is an overarching term encompassing several subtypes of blood cancers. Blood cells are produced in the bone marrow, the spongy material...
What are PARP inhibitors?
PARP inhibitors are a type of targeted therapy commonly used to treat breast cancer and ovarian cancer, among others. They target PARP, or...